Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56208 | 1.00 | MAPK1 (0.34) | MAPK1HIF1AACEALDH1A1TP53 | |
| SCHEMBL12815337 | 0.93 | TSHR (0.36) | MAPK1HIF1A | |
| SCHEMBL16569418 | 0.93 | MAPK1 (0.32) | MAPK1HIF1AALDH1A1TP53CYP3A4 | |
| SCHEMBL99517 | 0.93 | MAPK1 (0.31) | MAPK1HIF1A | |
| SCHEMBL16800392 | 0.93 | TSHR (0.36) | MAPK1HIF1A | |
| SCHEMBL29365358 | 0.93 | MAPK1 (0.31) | MAPK1HIF1A | |
| SCHEMBL13239258 | 0.93 | TSHR (0.36) | MAPK1HIF1A | |
| SCHEMBL574354 | 0.93 | TSHR (0.36) | MAPK1HIF1A | |
| SCHEMBL25092946 | 0.91 | MAPK1 (0.31) | MAPK1HIF1AALDH1A1TP53CYP3A4 | |
| SCHEMBL13734765 | 0.89 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325231-B1 | MULTIBRANCHED POLYALKYLENE GLYCOL POLYMER AND MANUFACTURING METHOD THEREOF, AND CEMENT ADMIXTURE | NIPPON CATALYTIC CHEM IND (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-8476341-B2 | Multi-branched polyalkylene glycol polymer, method for producing the same, and admixture for cement | NIPPON SHOKUBAI CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110160393-A1 | MULTI-BRANCHED POLYALKYLENE GLYCOL POLYMER, METHOD FOR PRODUCING THE SAME, AND ADMIXTURE FOR CEMENT | NIPPON SHOKUBAI CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325231-A1 | MULTIBRANCHED POLYALKYLENE GLYCOL POLYMER AND MANUFACTURING METHOD THEREOF, AND CEMENT ADMIXTURE | Nippon Shokubai Co., Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160393-A1 | MULTI-BRANCHED POLYALKYLENE GLYCOL POLYMER, METHOD FOR PRODUCING THE SAME, AND ADMIXTURE FOR CEMENT | VCL, XRCC5, BCR | MAPK1 2606/4885HIF1A 3901/4885ACE 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.